ȼøÀü³²´ëÇб³º´¿øÀº ¹æ»ç¼±Á¾¾çÇаú ³²ÅñٷÁ¤Àç¿í·Á¶ÀÍÁØ ±³¼öÆÀÀÌ ÃÖ±Ù ºÎ»ê ÆĶó´ÙÀ̽ºÈ£ÅÚ¿¡¼ ¿¸° ´ëÇѹæ»ç¼±Á¾¾çÇÐȸ Ãá°èÇмú´ëȸ¿¡¼ ‘ROJ(Radiation Oncology Journal)’ ³í¹®»óÀ» ¼ö»óÇß´Ù°í 31ÀÏ ¹àÇû´Ù.
‘ROJ ³í¹®»ó’Àº Àü³âµµ ´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö¿¡ °ÔÀçµÈ ³í¹® Áß¿¡ °¡Àå ¿ì¼öÇÑ ³í¹®À» ¼±Á¤ÇØ ¼ö¿©ÇÏ´Â »óÀÌ´Ù.
|
|
|
¡ã (¿ÞÂʺÎÅÍ)ȼøÀü³²´ëº´¿ø ¹æ»ç¼±Á¾¾çÇаú ³²ÅñٷÁ¤Àç¿í·Á¶ÀÍÁØ ±³¼ö |
³²ÅñٷÁ¤Àç¿í·Á¶ÀÍÁØ ±³¼öÆÀÀº ‘Á¤À§ üºÎ ¹æ»ç¼± Ä¡·á¸¦ ¹Þ´Â ±¹¼Ò °£¼¼Æ÷¾ÏÁ¾ ȯÀÚÀÇ ¿¹ÈÄ ÀÎÀڷμÀÇ PIVKA-II(PIVKA-II as a surrogate marker for prognosis in patients with localized hepatocellular carcinoma receiving stereotactic body radiotherapy)’¶ó´Â ³í¹®À¸·Î ¼ö»óÀÇ ¿µ¿¹¸¦ ¾È¾Ò´Ù.
ÀÌ ³í¹®Àº Á¤À§Ã¼ºÎ ¹æ»ç¼±Ä¡·á¸¦ ¹ÞÀº °£¾Ï ȯÀڵ鿡°Ô¼ °£¾ÏÇ¥ÁöÀÚÀÇ ÇϳªÀÎ PIVKA-II ¼öÄ¡°¡ Ä¡·á ÈÄ °¨¼ÒÇ߰ųª, ÀÏÁ¤ ¼öÄ¡ ÀÌÇÏ·Î ³·¾ÆÁø ȯÀÚ±ºÀÇ ±¹¼ÒÁ¾¾çÁ¦¾îÀ²°ú ¹«ÁøÇà»ýÁ¸À²ÀÌ À¯ÀÇÇÏ°Ô ¾çÈ£ÇßÀ½À» ±Ô¸íÇß´Ù.
< ÀúÀÛ±ÇÀÚ © ¿£ÁöƼºñ ¹«´ÜÀüÀç ¹× Àç¹èÆ÷±ÝÁö / ±â»çÁ¦º¸ ¹× ¹®ÀÇ ngtv@ngtv.tv > |